fda semaglutide warning september 2025 The U.S. Food and Drug Administration (FDA) has issued a to Novo Nordisk over its alleged failure to report adverse side effects, including death, in patients who took its GLP-1 medications FDA Finds No Increased Suicide

C., Huang, C

Importantly, previous functional studies have identified mutations in this region associated with IR phenotype ( After two years of glycemic stability, a slight worsening of metabolic control (HbA1c 7%- 53 mmol/mol) led to an increase of metformin dose (1275 mg/day) and the addition of sitagliptin (50 mg/day)

A study published in Current Neuropharmacology reveals a potential link between Glucagon-like Peptide-1 (GLP-1) receptor agonists, commonly used in drugs like Ozempic, and an increased risk of depression and suicidal ideation (SI)

These medications mimic natural GLP-1, a naturally occurring hormone produced by the body that plays a crucial role in how our bodies regulate blood sugar and appetite

Other restrictions may apply